The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585.
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - ALX Oncology; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Guardant Health; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
 
Yung-Jue Bang
Consulting or Advisory Role - Amgen; Astellas Pharma; Daewoong Pharmaceutical; Hanmi; SK Biopharm
 
Lucjan S. Wyrwicz
Honoraria - BeiGene; BMS; MSD
Consulting or Advisory Role - GlaxoSmithKline; SERVIER
Speakers' Bureau - BMS
Travel, Accommodations, Expenses - SERVIER
 
Sun Young Rha
Consulting or Advisory Role - Aadi; Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; Eutilex; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks
 
Takashi Oshima
Research Funding - Merck Sharp & Dohme (Inst)
 
Maria Di Bartolomeo
Honoraria - Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Servier
Consulting or Advisory Role - Novartis
Research Funding - Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Young-Kyu Park
No Relationships to Disclose
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Patricio Eduardo Yanez Weber
Honoraria - AstraZeneca (Inst); BMS CHILE (Inst); MSD (Inst); Sanofi/Regeneron (Inst)
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; MSD Oncology
Speakers' Bureau - AstraZeneca; BMS CHILE
 
Chia-Jui Yen
No Relationships to Disclose
 
Jean-Philippe Metges
Honoraria - Gilead Sciences; MSD Oncology; Pierre Fabre
Consulting or Advisory Role - Bayer; BeiGene; MSD Oncology
Travel, Accommodations, Expenses - MSD Oncology
 
Marcelo Garrido
Consulting or Advisory Role - AstraZeneca; MSD; Roche
Speakers' Bureau - Bayer; Bristol-Myers Squibb; MERCK
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - Roche
 
Markus H. Moehler
Honoraria - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer Schering Pharma; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Idience; Merck Serono; MSD Oncology; Pierre Fabre; Roche/Genentech; Sanofi; Servier; Transcenta; Triptych Health Partners
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD; Nordic Group; SERVIER; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; BeiGene; ESMO; German Cancer Society; Merck Serono; MSD; Roche; Sanofi Pasteur
 
Sharon Pelles-Avraham
No Relationships to Disclose
 
Wei-Peng Yong
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Astellas Pharma; AstraZeneca
Speakers' Bureau - AstraZeneca; BMS; DKSH; Eisai; MSD Oncology; Novartis
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Experimental Drug Development Centre (EDDC)/A*STAR (Inst); MSD (Inst); Novartis (Inst); SCG Cell Therapy (Inst)
 
Andrea Spallanzani
No Relationships to Disclose
 
Erin Jensen
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Radha Krishnan
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Chie-Schin Shih
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Frankfurter Institut für Klinische Krebsforschung IKF GmbH; Immutep
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; Eli Lilly Germany; Merck Sharp & Dohme
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Immutep; Ipsen; Lilly; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma